AMENDMENTS TO THE SPECIFICATION

IN THE TITLE OF THE INVENTION:

Method for Down-Regulating GDF-8 Activity Using Immunogenic GDF-8 Analogues

IN THE SPECIFICATION:

Before line 1 of the specification **(after the Title)**, please insert the following new paragraph:

This application is a national phase under 35 U.S.C § 371 of PCT International Application No. PCT/DK00/00413, which was filed in English and which has an International filing date of July 20, 2000, which designated the United States of America. This application also claims priority of Application No. PA 1999 01014 filed in DENMARK on July 20, 1999 and Application No. 60/145,275 filed in the United States of America on July 26, 1999 under 35 U.S.C. § 119.

On page 25, paragraph beginning on line 25, please amend the paragraph as follows:

One especially preferred PADRE peptide is the one having the amino acid sequence AKFVAAWTLKAAA (SEQ ID NO: 24) or an immunologically effective subsequence thereof. This, and other epitopes having the same lack of MHC restriction are preferred T-cell epitopes which should be present in the GDF-8 analogues used in the inventive method. Such super-promiscuous epitopes will allow for the most simple embodiments of the invention wherein only one single modified GDF-8 is presented to the vaccinated animal's immune system.

On page 26, paragraph beginning on line 1, please amend the paragraph as follows:

As mentioned above, the modification of GDF-8 can also include the introduction of a first moiety which targets the modified GDF-8 to an APC or a B-lymphocyte. For instance, the first moiety can be a specific binding partner for a B-lymphocyte specific surface antigen or for an APC specific surface antigen. Many such specific surface antigens are known in the art. For instance, the moiety can be a carbohydrate for which there is a receptor on the B-lymphocyte or on the APC (e.g. mannan or mannose). Alternatively, the second moiety can be a hapten. Also an antibody fragment which specifically recognizes a surface molecule on APCs or lymphocytes can be used as a first moiety (the surface molecule can e.g. be an ~~FC~~Fcγ receptor of macrophages and monocytes, such as ~~FCRI~~FcγRI or, alternatively any other specific surface marker such as CD40 or CTLA-4). It should be noted that all these exemplary targeting molecules can be used as part of an adjuvant also, cf. below.